Connection Between CDC20 Expression and Hepatocellular Carcinoma Prognosis

Abstract

Background Hepatocellular carcinoma (HCC) occurs frequently in China, with high morbidity and mortality. Cell division cycle 20 homolog ( CDC20 ) is reportedly related to many cancers. In this study, we discuss a potential link of CDC20 expression to HCC patients’ prognoses. Material/Methods Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to assess CDC20 expression in HCC and the paired noncancerous tissues. Chi-square analysis was used to assess potential association of CDC20 expression with clinicopathologic profiles among HCC patients. The overall survival for HCC patients with different CDC20 expressions was assessed using the Kaplan-Meier method. To evaluate the prognostic value for HCC patients, Cox regression analyses were performed. Results The expression of CDC20 was elevated among HCC specimens compared with adjacent noncancerous ones ( P <0.05). The expression of CDC20 was significantly related to differentiation ( P <0.001), tumor node metastasis stage ( P <0.001), and lymphatic metastasis ( P <0.001). Moreover, HCC patients with high CDC20 expression had dismal overall survival rates compared with low CDC20 expression ( P <0.05). CDC20 alone could forecast HCC prognoses according to multivariable Cox regression analysis (hazard ratio=2.354, 95% confidence interval=1.177–4.709, P =0.016). Conclusions Overexpressed CDC20 may act as a reliable biomarker for dismal prognoses among HCC patients.

Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic

“…It is the target of the spindle assembly checkpoint (SAC) and the key cofactor of the anaphase-promoting complex or cyclosome (APC/C) E3 ubiquitin ligase, thus regulating APC/C ubiquitin activity on specific substrates for their subsequent degradation by the proteasome (62). CDC20 is overexpressed in tumor cells and acts as a poor prognostic factor in multiple cancers (63,64). It further increased after radiation and has been reported to increase radiation resistance via regulating B-cell lymphoma-2 (Bcl-2)/Bcl-2-associated X protein (Bax), forkhead box proteins O1 (FoxO1), or myeloid cell leukemia sequence 1 (Mcl-1)/p-CHK1 in different cancer types (65)(66)(67).…”

The intercorrelation among CCT6A, CDC20, CCNB1, and PLK1 expressions and their clinical value in papillary thyroid carcinoma prognostication

“…In terms of CDC20, CCNB1, and PLK1, they also have been indicated as potential prognostic markers in carcinoma patients as well. 25 , 26 , 27 For instance, CDC20 is upregulated in tumor tissue compared to non‐tumor tissue from HCC patients, also increased CDC20 is associated with lymph node metastasis, advanced pTNM stage, and reduced OS in HCC patients. 25 Besides, CCNB1 is reported to be upregulated in tumor tissue from HCC patients, and enhanced CCNB1 is related to declined DFS and OS in HCC patients as well.…”

“… 25 , 26 , 27 For instance, CDC20 is upregulated in tumor tissue compared to non‐tumor tissue from HCC patients, also increased CDC20 is associated with lymph node metastasis, advanced pTNM stage, and reduced OS in HCC patients. 25 Besides, CCNB1 is reported to be upregulated in tumor tissue from HCC patients, and enhanced CCNB1 is related to declined DFS and OS in HCC patients as well. 26 Moreover, PLK1 is related to reduced DFS and OS in ovarian carcinoma patients, also it is independently associated with shorter OS by multivariate Cox's regression analysis.…”

Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer

“…Results of this study revealed that BUB1 and CDC20 had significantly higher expression levels in platinum-sensitive samples than that of platinum-resistant in both two GEO datasets. Accumulating evidence indicates that there is a strong link between abnormal upregulation of CDC20 and various types of tumors [ 41–43 ]. CDC20 knockdown was shown to sensitize cancer cells to chemotherapy and radiation therapy [ 44 , 45 ].…”